US 11,938,164 B2
Exosome-based cancer assays
Gerald V. Denis, Arlington, MA (US); Louis C. Gerstenfeld, Canton, MA (US); Naser Jafari, Boston, MA (US); and Tova Meshulam, Boston, MA (US)
Assigned to TRUSTEES OF BOSTON UNIVERSITY
Filed by TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed on Apr. 6, 2022, as Appl. No. 17/714,295.
Claims priority of provisional application 63/277,766, filed on Nov. 10, 2021.
Claims priority of provisional application 63/171,689, filed on Apr. 7, 2021.
Prior Publication US 2022/0331390 A1, Oct. 20, 2022
Int. Cl. A61K 38/00 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 38/005 (2013.01) [A61K 38/217 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 24 Claims
 
1. A method of treating an overweight, obese or diabetic subject with cancer, the method comprising administering
(i) a glucose-controlling medication, or obesity medication and/or
(ii) CT scans at a frequency of higher than one CT scan every 6 months to an overweight, obese or diabetic subject with cancer determined to have
(a) an expression level of at least one gene selected from: miR374a-5p, miR-93-5p, miR-28-3p, miR-let-7b-3p, TSP5, SNAI1, TWIST1, SNAI2, vimentin (VIM), ZEB1 and AHNAK in an exosome originating from the adipose tissue or adipocytes of the subject, wherein the expression level of the at least one gene is increased relative to a reference; or
(b) an expression level of at least one gene selected from: miR424-5p, miR-326, miR-27a-3p, miR320b and miR320d in an exosome originating from the adipose tissue or adipocytes of the subject, wherein the expression level of the at least one gene is decreased relative to a reference.